Login / Signup

Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.

Marcello MocciaGiuseppina AffinitoGiulia BereraGiuseppina MarrazzoRaffaele PiscitelliAntonio CarotenutoMaria PetraccaRoberta LanzilloMaria TriassiVincenzo Brescia MorraRaffaele Palladino
Published in: Journal of neurology (2022)
Ocrelizumab was among the most frequently prescribed DMTs, with 26% prescriptions to treatment-naïve patients, suggesting its relevance in addressing unmet clinical needs (e.g., first approved treatment for primary progressive MS). Ocrelizumab was associated with the highest persistence, confirming its favorable benefit-risk profile. Costs for ocrelizumab were lower than those associated to similarly effective DMTs, in absence of changes in healthcare resource utilization.
Keyphrases